Skip to main content

Table 2 Serious adverse events including bleeding events through clinical trials

From: The safety profile of drotrecogin alfa (activated)

 

Placebo-controlled studies

Open-labela

 

PROWESS

ADDRESS

ENHANCE

XPRESS

Adverse events

DrotAA (n = 850)

Placebo (n = 840)

DrotAA (n = 1,317)

Placebo (n = 1,293)

DrotAA (n = 2,378)

DrotAA (n = 1,935)

Study drug infusion period*

   Serious events

58 (6.8)

55 (6.5)

75 (5.7)

78 (6.0)

166 (7.0)

128 (6.6)

   Serious bleeds

20 (2.4)

8 (1.0)

31 (2.4)

15 (1.2)

85 (3.6)

46 (2.4)

   CNS bleeds

2 (0.2)

0

4 (0.3)

3 (0.2)

15 (0.6)

6 (0.3)

Days 0 through 28

   Serious events

106 (12.5)

102 (12.1)

182 (13.8)

183 (14.2)

319 (13.4)

256 (13.2)

   Serious bleeds

30 (3.5)

17 (2.0)

51 (3.9)

28 (2.2)

155 (6.5)

88 (4.5)

   CNS bleeds

2 (0.2)

1 (0.1)

6 (0.5)

5 (0.4)

35 (1.5)

17 (0.9)

  1. *In PROWESS and ENHANCE, the study drug infusion period was defined as the actual infusion plus 1 day. In ADDRESS, RESOLVE and XPRESS, the study drug infusion period was defined as study days 0 through 6. Values are expressed as n (%). aENHANCE was an open-label study. XPRESS was a placebo-controlled study of the co-administration of heparin with drotrecogin alfa (activated); the drug under study was heparin; open-label drotrecogin alfa (activated) was administered to all patients. ADDRESS, Efficacy and Safety of Drotrecogin alfa [activated] in Adult Severe Sepsis Patients at Low Risk of Death; CNS, central nervous system; DrotAA, drotrecogin alfa (activated); ENHANCE, Extended Evaluation of Recombinant Human Activated Protein C, drotrecogin alfa (activated); PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; XPRESS, Xigris and Prophylactic Heparin Evaluation in Severe Sepsis. Modified with permission from Williams MD, Macias W, Rustige J: Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions. Intensive Care Med 2007, 33:1487–1488. © Springer-Verlag.
Back to article page

Critical Care

ISSN: 1364-8535